Sign in
TerminatedPhase 1

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Key facts

Who runs it
Amgen
Where
Houston, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
7 people enrolled
Started
14 Nov 2022
Ended
19 Dec 2023
Type of study
Interventional, 3 groups
Treatments tested
  • AMG 176
  • Azacitidine
Record updated
14 July 2025
Why it stopped
Sponsor decision, unrelated to safety

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age >= 18 years of age
  • For Part 1, participants have R/R MDS post-HMA failure, defined as prior receipt of 4 cycles of HMA therapy (including but not limited to decitabine, azacitidine, investigational HMAs such as SGI-110, and oral HMAs such as oral decitabine and cedazuridine [ASTX727] and oral azacitidine [CC-486]) with failure to attain a response or progression of disease or relapse at any time after prior response to HMA therapy; Note: participants with HR-CMML (CMML-1 or 2 by World Health Organization [WHO]) are eligible. Hydroxyurea administration will be allowed on the study to lower the white cell count to <= 10 000/μL prior to the initiation of therapy
  • For Part 2, participants will be divided into 2 cohorts:; HMA Failure Cohort: participants with R/R MDS post-HMA failure. Participants who have previously received venetoclax are eligible and will be stratified accordingly in the HMA failure cohort; Newly Diagnosed Cohort: Participants with treatment-naïve newly diagnosed HR-MDS (revised International Prognostic Scoring System [IPSS-R] score >3.5) are eligible for enrollment only after all prior cohorts have been completed. Hydroxyurea administration will be allowed on the study to lower the white cell count to <= 10 000/μL prior to the initiation of therapy. Participants with HR-CMML (CMML-1 or 2 by WHO) are eligible

Who cannot take part

  • Excluded prior and/or concomitant therapies as listed in the full list of criteria
  • Participants who are fit and deemed eligible by the investigator for intensive salvage therapy
  • History of other malignancy within the past 2 years prior to enrollment (with some exceptions as listed in full list of criteria)
  • Participants with newly diagnosed MDS with Revised International Prognostic Scoring System (IPSS-R) lower-risk category (IPSS-R score < 3.5)
  • Participants with CMML-0 by WHO

Where in United States

  • University of Texas - MD Anderson Cancer CenterHouston, United States

About the trial

What the trial wants to find out

The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia (HR-MDS/CMML).

The 3 groups in the trial

  • Part 1A - AMG 176 Monotherapy (Dose Exploration)Treatment being tested

    Two dose levels of AMG 176 will be tested in Part 1A to find the optimal biological dose/minimum safe biologically effective dose (OBD/MSBED).

    Treatment: AMG 176

  • Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration)Treatment being tested

    After the OBD is found in Part 1A, two dose levels of AMG 176 in combination with azacitidine will be tested in Part 1B to find the OBD/MSBED.

    Treatment: AMG 176 and Azacitidine

  • Part 2 - AMG 176 and Azacitidine Combination Therapy (Dose Expansion)Treatment being tested

    After the completion of Part 1, the Part 2 dose expansion phase will begin at the OBD/MSBED identified in Part 1. Venetoclax-naïve and venetoclax-exposed R/R HR-MDS participants after HMA failure will be enrolled along with participants with newly diagnosed HR-MDS/CMML.

    Treatment: AMG 176 and Azacitidine

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Study of AMG 176 as Monotherapy and in Combination With Azacitidine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Record updated
14 July 2025